RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Swiss pharma giant Roche (ROG: SIX) on Friday released positive top-line one-year results from the open-label, single-arm ...

According to data presented in a late-breaking oral presentation at the American Academy of Ophthalmology 2024 Annual Meeting ...

Roche (RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo ...

Results were consistent with the phase III YOSEMITE and RHINE DME studies. 5 A secondary endpoint showed robust retinal drying with Vabysmo across these racial and ethnic groups, who, on average ...